IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs Meropenem in the Treatment of Complicated Intraabdominal Infections

BACKGROUND: Increasing antimicrobial resistance among pathogens that cause complicated intraabdominal infections (cIAIs) supports the development of new antimicrobials. Eravacycline, a novel member of the fluorocycline family, is active against multidrug-resistant bacteria including extended-spectru...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomkin, Joseph S, Gardovskis, Janis, Lawrence, Kenneth, Montravers, Philippe, Sway, Angie, Evans, David, Tsai, Larry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735687/
https://www.ncbi.nlm.nih.gov/pubmed/30561562
http://dx.doi.org/10.1093/cid/ciy1029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6735687/
https://www.ncbi.nlm.nih.gov/pubmed/30561562
http://dx.doi.org/10.1093/cid/ciy1029

Ejemplares similares